Skip Ribbon Commands
Skip to main content
Navigate Up
Sign In

Dear colleag​​​ues,

 

The Belgian Early Warning System Drugs (BEWSD) was informed of the analysis of several ecstasy tablets, containing high amounts of MDMA.

These tablets were analysed at the National Institute for Criminalistics and Criminology (NICC-INCC).

Also, a green liquid was submitted to the Modus Vivendi project in Brussels, and analysed by the WIV-ISP Medicines laboratory.

It contained 2C-E, a new psychoactive substance with properties comparable with 2C-B, a hallucinogenic amphetamine derivative (more info in the fact sheet: pdf​).

 

The MDMA tablets have the following characteristics:

Tablet 1

Logo: “Domino”

Colour: Blue

Shape: Rectangle

Length: 12.1 mm

Thickness: 4.5 mm

Weight: 402mg

MDMA contents: 152.3mg MDMA base

 

Tablet 2

Logo : « Bentley »

Colour: Purple

Shape: “B”

Diameter: 10.3 mm

Thickness: 5 mm

Weight: 347.7 mg

MDMA contents: 158 mg MDMA base

 


Also, several tablets have been analysed containing no active substance at all. These were mostly tablets with the UPS logo.

The BEWSD would like to warn for these tablets, and for highly dosed MDMA tablets in general.

Please inform your networks, and don’t hesitate to contact us if you receive similar signals.

 

Kind regards,

 

Peter

Dr. Apr. Peter Blanckaert

Coordinator Belgian Early Warning System on Drugs

DO Public Health&Surveillance, Drugs Program (BMCDDA)

Juliette Wytsmanstraat 14 | 1050 Brussels

T + 32 2 642 54 08 | F + 32 2 642 54 10 | GSM Wacht +32 475 84 68 16

E-mail: peter.blanckaert@wiv-isp.be

Skype: wiv-isp.peter.blanckaert

Institut Scientifique de Santé Publique

Wetenschappelijk Instituut Volksgezondheid
Scientific Institute of Public Health
www.wiv-isp.be


DISCLAIMER

 

The information in this message is exclusively meant for the EWS-network, and was sent to you, as a member of this network, in a confidential way.

Therefore the information in this message may not be copied, transferred or made public without the prior permission of the WIV-ISP.

The WIV-ISP takes responsibility for the editing of a press release, if considered as necessary in the framework of its mission.

The information contained in this document is also available on the BEWSD-website (with corresponding pdf-files and analytical data).

This part of the website is not accessible for the general public.

A login can be requested by contacting ews.drugs@wiv-isp.be.

  

Information: BEWSD Alert levels

 

​The BEWSD has d​​​​ecided to distinguish its alert messages depending on the severity of the reported information.

The following 4 alert levels are used, and will always be indicated between brackets ([]) in the subject line of the alert message.